Long-Term Debt and Notes Payable - Additional Information (Detail)					1 Months Ended		3 Months Ended	9 Months Ended
	Apr. 01, 2019 USD ($)	Oct. 01, 2017 USD ($)	Apr. 01, 2017 USD ($)	Mar. 02, 2017 USD ($) Subsidiary $ / shares shares	May 31, 2019 USD ($)	May 31, 2016 USD ($) BoardofDirector	Jun. 30, 2019 USD ($)	Sep. 30, 2019 USD ($) shares	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Line of Credit Facility [Line Items]
Long-term debt								$ 62,236,000		$ 45,650,000
Repayments of long-term debt								14,533,000
Write off of unamortized debt issuance costs								137,000
Debt issuance costs resulting from an amendment fee paid lender								218,000
Increase in additional paid-in capital due to issuance of warrant							$ 178,000
Interest cost								$ 6,121,000	$ 6,482,000
Unsecured Promissory Notes
Line of Credit Facility [Line Items]
Debt instrument, maturity date						Apr. 01, 2019
Debt instrument, interest rate						7.00%
Proceeds from issuance of notes						$ 25,000,000
Debt instrument, payable number | BoardofDirector						2
PIK interest payment		$ 1,043,000	$ 997,000
Repayments of outstanding principal balance	$ 27,040,000
Credit Agreement | Unsecured Promissory Notes
Line of Credit Facility [Line Items]
Debt instrument, payment terms								Interest payments at 8.00% until the lenders under the New Credit Agreement receive two consecutive semi-annual cash interest payments.
Debt instrument, frequency of periodic payment								Semi-annual
Debt instrument, payment-in-kind interest rate				8.00%
Wilks
Line of Credit Facility [Line Items]
Repayments of long-term debt					$ 14,533,000
Wilks | Credit Agreement
Line of Credit Facility [Line Items]
Long-term debt				$ 65,000,000	65,000,000
Debt instrument, maturity date								Dec. 31, 2022
Debt instrument, interest rate				9.00%
Number of operating subsidiaries | Subsidiary				2
Unamortized debt issuance costs								$ 628,000
Warrants exercise price per share | $ / shares				$ 14.91
Warrants expiration date				Dec. 31, 2024
Percentage of common stock outstanding owned								10.50%
Percentage of common stock outstanding would hold upon exercise of warrant to purchase additional shares								12.10%
Increase in additional paid-in capital due to issuance of warrant								$ 3,871,000
Wilks | Credit Agreement | Maximum
Line of Credit Facility [Line Items]
Warrant entitles to purchase shares of the common stock | shares				523,022				523,022
Wilks | Credit Agreement | Warrant
Line of Credit Facility [Line Items]
Unamortized original issue discount								$ 2,136,000
Wilks | Amended Credit Agreement
Line of Credit Facility [Line Items]
Long-term debt					33,000,000
Unamortized debt issuance costs								628,000
Warrants exercise price per share | $ / shares				$ 4.00
Increase in additional paid-in capital due to issuance of warrant								178,000
Wilks | Amended Credit Agreement | Warrant
Line of Credit Facility [Line Items]
Unamortized original issue discount								609,000
Wilks and Equify | Amendment Credit Agreement and Equify Note
Line of Credit Facility [Line Items]
Long-term debt								65,000,000
Equify Note | Amended Credit Agreement
Line of Credit Facility [Line Items]
Long-term debt					$ 32,000,000
Equify Note | Wilks
Line of Credit Facility [Line Items]
Debt instrument, maturity date					Dec. 31, 2022
Debt instrument, interest rate					9.00%
Standby Letters of Credit | Wilks and Equify | Amended Credit Agreement
Line of Credit Facility [Line Items]
Letters of credit outstanding								$ 7,889,000		$ 2,625,000